Management of digital ulcers from systemic scleroderma. Recommendations of a multidisciplinary group of experts;Prise en charge des ulcères digitaux de la sclérodermie systémique. Recommandations d'un groupe pluridisciplinaire d'experts

Presse Medicale

Volumn 37, Issue 2 PART 2, 2008, Pages 271-285

  Francès, Camille ^a   Allanore, Yannick ^b   Cabane, Jean ^c   Carpentier, Patrick ^d   Dumontier, Christian ^c   Hachulla, Éric ^e   Hatron, Pierre Yves ^e   Lipsker, Dan ^f   Meaume, Sylvie ^g   Mouthon, Luc ^b   Senet, Patricia ^g   Sibilia, Jean ^f  

^a HÔPITAL TENON   (France)

^b Hôpital Cochin ^*  (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g HÔPITAL CHARLES FOIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTIINFECTIVE AGENT; BOSENTAN; BREFELDIN A; CHLORHEXIDINE; CLINDAMYCIN; EMLA; FENTANYL; GENTAMICIN; ILOPROST; LIDOCAINE; LINEZOLID; MORPHINE; NIFEDIPINE; PARACETAMOL; PARAFFIN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RIFAMPICIN; SILDENAFIL; SULFADIAZINE SILVER; TEICOPLANIN; TRAMADOL; UNINDEXED DRUG; VALNOCTAMIDE; VANCOMYCIN; VASODILATOR AGENT; LOCAL ANESTHETIC AGENT;

ANALGESIA; ANESTHESIA; ANTISEPSIS; BACTERIAL INFECTION; BACTERIUM CULTURE; BANDAGES AND DRESSINGS; CLINICAL FEATURE; COMPRESSION BANDAGE; DEBRIDEMENT; ECHOCARDIOGRAPHY; ECZEMA; EMPHYSEMA; EXUDATE; FINGER ARTHROPLASTY; FINGER ULCER; FLUORESCENCE ANGIOGRAPHY; FOOT ULCER; GRAFT NECROSIS; HAND DISEASE; HUMAN; HYDROCOLLOID DRESSING; HYGIENE; INFECTION PREVENTION; LONG TERM CARE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOPHYSIOLOGY; PATIENT EDUCATION; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SCINTIGRAPHY; SHORT SURVEY; SKIN EXFOLIATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUPERINFECTION; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WOUND CARE; WOUND DRAINAGE; ELECTROSTIMULATION THERAPY; FINGER; REVIEW; SKIN ULCER;

ANALGESIA; ANESTHETICS, LOCAL; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BANDAGES, HYDROCOLLOID; ELECTRIC STIMULATION THERAPY; FINGERS; HUMANS; SCLERODERMA, SYSTEMIC; SKIN ULCER; VASODILATOR AGENTS;

EID: 41949107360     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.07.006     Document Type: Article

References (80)

1. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1, 012 Italian patients. Medicine 81 (2002) 139-153
2. Nietert P.J., Mitchell H.C., Bolster M.B., Shaftman S.R., Tilley B.C., and Silver R.M. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 3 (2006) 263-268
3. Stafford L., Englert H., Gover J., and Bertouch J. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis 57 (1998) 476-479
4. Rodnan G.P., Myerowitz R.L., and Justh G.O. Morphological changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine 59 (1980) 393-408
5. Cazalets C., Cador B., Rolland Y., Decaux O., Guggenbulgh P., Chaperon C., et al. Exploration de la microcirculation pulpaire par echo-doppler digital chez des patients présentant une maladie de Raynaud ou une sclérodermie. J Mal Vasc 29 (2004) 12-20
6. Herrick A.L. Pathogenesis of Raynaud's phenomenon. Rheumatology 44 (2005) 587-596
7. Avouac J., Guerini H., Assous N., Chevrot A., Kahan A., and Allanore Y. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 65 (2006) 1088-1092
8. Wolkenstein P., and Vaillant L. Les antiseptiques en peau lésée. Ann Dermatol Venereol 123 (1996) 343-348
9. Machet L., Wolkenstein P., and Vaillant L. Topical antibiotics used in dermatology: efficiency, indications and adverse events. Ann Dermatol Vénéréol 127 (2000) 425-431
10. Hinman C.D., and Maibach H. Effect of air exposure and occlusion on experimental human skin wounds. Nature 200 4904 (1963) 377-378
11. O. Toole E.A., Marinkovich M.P., Peavey C.L., Amieva M.R., Furthmayr H., Mustoe T.A., et al. Hypoxia increases keratinocytes mobility on connective tissue. J Clin Invest 100 (1997) 2881-2891
12. Milburn P.B., Singer J.Z., and Milburn M.A. Treatment of scleroderma skin ulcers with a hydrocolloid membrane. J Am Acad Dermatol 21 (1989) 200-204
13. Ward W.A., and Van Moore A. management of finger ulcers in scleroderma. J Hand Surg [Am] 20 (1995) 868-872
14. Ozgocmen S., Kaya A., and Coskun B.K. Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma). Clin Rheumatol 25 3 (2006) 378-379
15. Azma T., and Okida M. Does lidocaine provoke clinically significant vasospasm?. Acta Anaesthesiol Scand 47 (2003) 1174-1175
16. Ward W.A., and Van Moore A. Management of finger ulcers in scleroderma. J Hand Surg [Am] 20 5 (1995) 868-872
17. Chung L., and Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 5 (2006) 125-128
18. Clements P.J., Medsger T.A., and Feghali C.A. Cutaneous involvement in systemic sclerosis. In: Clements P.J., and Furst D.E. (Eds). Systemic sclerosis. 2nd ed. (2004), Lippincott, Williams and Wilkins, Philadelphia 129-150
19. Jones N.F. Surgical treatment of the hand in systemic sclerosis. In: Clements P.J., and Furst D.E. (Eds). Systemic sclerosis. 2nd ed. (2004), Lippincott, Williams and Wilkins, Philadelphia 269-277
20. O'Meara S., Cullum N., Majid M., and Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess 4 21 (2000) 1-237
21. Kessler L., Piémont Y., Ortega F., Lesens O., Boeri C., Averous C., et al. Comparison of microbiological results of needle puncture versus. superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabet Med 23 (2006) 99-102
22. Senneville E., Melliez H., Beltrand E., Legout L., Valette M., Cazaubiel M., et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis 42 (2006) 57-62
23. Thompson A.E., Shea B., Welch V., Fenlon D., and Pope J.E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44 (2001) 1841-1847
24. Meyrick Thomas R.H., Rademaker M., Grimes S.M., MacKay A., Kovacs I.B., et al. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis. Br J Dermatol 117 (1987) 237-241
25. Rademaker M., Cooke E.D., Almond N.E., Beacham J.A., Smith R.E., Mant T.G.K., et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298 (1989) 561-564
26. MacHugh N.J., Csuka M., Watson H., Belcher G., Amadi A., Ring E.F., et al. Infusion of, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 47 (1988) 43-47
27. Yardumian D.A., Isenberg D.A., Rustin M., Belcher G., Snaith M.L., Dowd P.M., et al. Successful treatment of Raynaud's syndrome with iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol 27 (1988) 220-226
28. Kyle M.V., Belcher G., and Hazleman B.L. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 19 (1992) 1403-1406
29. Wigley F.M., Seibold J.R., Wise R.A., McCloskey D.A., and Dole W.P. Intravenous iloprost treatment of Raynaud's ph enomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19 (1992) 1407-1414
30. Wigley F.M., Wise R.A., Seibold J.R., McCloskey D.A., Kujala G., Medsger Jr. T.A., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120 (1994) 199-206
31. Torley H.I., Madhok R., Capell H.A., Brouwer R.M.L., Maddison P.J., Black C.M., et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50 (1991) 800-804
32. Scorza R., Caronni M., Mascagni B., Berruti V., Bazzi S., Micallef E., et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19 (2001) 503-508
33. Bettoni L., Geri A., Airo P., Danieli E., Cavazzana I., Antonioli C., et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21 (2002) 244-250
34. Milio G., Corrado E., Genova C., Amato C., Raimondi F., Almasio P.L., et al. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. Rheumatology 45 (2006) 999-1004
35. Black C.M., Halkier-Sorensen L., Belch J.J., Ullman S., Madhok R., Smit A.J., et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 37 (1998) 952-960
36. Wigley F.M., Korn J.H., Csuka M.E., Medsger Jr. T.A., Rothfield N.F., Ellman M., et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 41 (1998) 670-677
37. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. J Rheumatol 26 (1999) 2173-2178
38. Cabane J., Boue F., Godeau P., Lecompte T., Charpentier M.C., Samama M., et al. Essai de traitement du phenomene de Raynaud severe par la prostacycline (PGI2). Rev Med Interne 6 (1985) 581-589
39. Kingma K., Wollersheim H., and Thien T. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained. J Cardiovasc Pharmacol 26 (1995) 388-393
40. Chung L., and Fiorentino D. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol 54 (2006) 880-882
41. Gore J., and Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital secondary to systemic sclerosis. Ann Rheum Dis 64 (2005) 1387
42. Fries R., Shariat K., von Wilmowsky H., and Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112 (2005) 2980-2985
43. Wise R.A., Wigley F.M., White B., Leatherman G., Zhong J., Krasa H., et al. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized cross-over study. Arthritis Rheum 50 (2004) 3994-4001
44. Roald O.K., and Seem E. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Br Med J (Clin Res Ed) 289 (1984) 577-579
45. Lukac J., Rovensky J., Tauchmannova H., and Zitnan D. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial. Drugs Exp Clin Res 11 (1985) 659-663
46. Ortonne J.P., Torzuoli C., Dujardin P., and Fraitag B. Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial. Br J Dermatol 120 (1989) 261-266
47. Pope J., Fenlon D., Thompson A., Shea B., Furst D., Wells G., et al. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2 (2000) CD000954
48. Anderson M.E., Moore T.L., Hollis S., Jayson M.I., King T.A., and Herrick A.L. Digital vascular response to topical glyceryl trinitrate as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology 41 (2002) 324-328
49. Kan C., Akimoto S., Abe M., Okada K., and Ishikawa O. Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis. Ann Rheum Dis 61 (2002) 177-179
50. Herrick A.L., Gush R.J., Tully M., and Jayson M.I. A controlled trial of the effect of topical glyceryl trinitrate on skin blood flow and skin elasticity in scleroderma. Ann Rheum Dis 53 (1994) 212
51. Dziadzio M., Denton C.P., Smith R., Howell K., Blann A., Bowers E., et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel group, controlled trial. Arthritis Rheum 42 (1999) 2646-2655
52. Ciompi M.L., Bazzichi L., Melchiorre D., De Giorgio F., Bondi F., and Puccetti L. A placebo-controlled study on urokinase therapy in systemic sclerosis. Biomed Pharmacother 50 (1996) 363-368
53. Sambo P., Amico D., Giacomelli R., Matucci-Cerinic M., Salsano F., Valentini G., et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 28 (2001) 2257-2262
54. Giuggioli D., Magistro D., Colaci M., Franciosi U., Caruso A., and Ferri C. Fattori di crescita e terapia delle ulcere cutanee correlate alla sclerosi sistemica: uso del G-CSF in una casistica di 26 pazienti. Reumatismo 58 (2006) 26-30
55. Berglund B., Swanbeck G., and Hedin H. Low molecular weight dextran therapy for digital ischemia due to collagen vascular disease. Dermatologica 163 4 (1981) 353-357
56. Filho J.P., Sampaio-Barros P.D., Parente J.B., Menezes F.H., Poterio G.B., Samara A.M., et al. Rhythmic external compression of the limbs: a method for healing cutaneous ulcers in systemic sclerosis. J Rheumatol 25 8 (1998) 1540-1543
57. Francaviglia N., Silvestro C., Maiello M., Bragazzi R., and Bernucci C. Spinal cord stimulation for the treatment of progressive systemic sclerosis and Raynaud's syndrome. Br J Neurosurg 8 (1994) 567-571
58. Gilbart M.K., Jolles B.M., Lee P., and Bogoch E.R. Surgery of the hand in severe systemic sclerosis. J Hand Surg Br 29 (2004) 599-603
59. Jones N.F., Imbriglia J.E., Steen V.D., and Medsger T.A. Surgery for scleroderma of the hand. J Hand Surg Am 12 (1987) 391-400
60. Bogoch E.R., and Gross D.K. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 32 (2005) 642-648
61. Melone Jr. C.P., McLoughlin J.C., and Beldner S. Surgical management of the hand in scleroderma [Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes]. Curr Op Rheumatol 11 (1999) 514-520
62. Nalebuff E.A. Surgery in Patients with systemic sclerosis of the Hand. CORR 366 (1999) 91-97
63. Entin M.A., and Wilkinson R.D. Scleroderma hand. A reappraisal. Orthop Clin North Am 4 (1973) 1031-1038
64. Chammas M., Meyer zu Reckendorf G., and Allieu Y. Compression of the ulnar nerve in Guyon's canal by pseudotumoral calcinosis in systemic scleroderma. J Hand Surg [Br] 20 (1995) 794-796
65. Thurman R.T., Jindal P., and Wolff T.W. Ulnar nerve compression in Guyon's canal caused by calcinosis in scleroderma. J Hand Surg [Am] 16 (1991) 739-741
66. Matsumoto A.K., Moore R., Alli P., and Wigley F.M. Three cases of osteonecrosis of the lunate bone of the wrist in scleroderma. Clin Exp Rheumatol 17 (1999) 730-732
67. Segalman K.A., and Clark G.L. Un-united fractures of the distal radius: a report of 12 cases. J Hand Surg [Am] 23 (1998) 914-919
68. Rosenbaum L.H., Swartz W.M., Rodnan G.P., and Medsger Jr. T.A. Wrist drop in progressive systemic sclerosis (scleroderma): complete rupture of the extensor tendon mechanism. Arthritis Rheum 28 (1985) 586-589
69. Wilgis E.F.S. Evaluation and treatment of chronic digital ischemia. Ann Surg 193 (1981) 693-696
70. Tomaino M.M., Goitz R.J., and Medsger T.A. Surgery for ischemic pain and Raynaud's' phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery 21 (2001) 75-79
71. el-Gammal T.A., and Blair W.F. Digital periarterial sympathectomy for ischaemic digital pain and ulcers. J Hand Surg [Br] 16 (1991) 382-385
72. Tomaino M.M. Digital arterial occlusion in scleroderma: is there a role for digital arterial reconstruction?. J Hand Surg [Br] 25 (2000) 611-613
73. Tomaino M.M., King J., and Medsger T. Rationale for and efficacy of digital arterial reconstruction in scleroderma: report of two cases. J Reconstr Microsurg 18 (2002) 263-268
74. Schlenker J.D., Clark D.D., and Weckesser E.C. Calcinosis circumscripta of the hand in scleroderma. J Bone Joint Surg Am 55 (1973) 1051-1056
75. Mendelson B.C., Linscheid R.L., Dobyns J.H., and Muller S.A. Surgical treatment of calcinosis cutis in the upper extremity. J Hand Surg 2 (1977) 318-324
76. Bottomley W.W., Goodfield M.J., and Sheehan-Dare R.A. Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser. Br J Dermatol 135 (1996) 302-304
77. Polio J.L., and Stern P.J. Digital nerve calcification in CREST syndrome. J Hand Surg [Am] 14 (1989) 201-203
78. Korn J.H., Mayes M., Matucci Cerinic M., Rainisio M., Pope J., Hachulla E., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004) 3985-3993
79. Seibold JR, Denton CP, Furst DE, Matucci-Cerinic M, Mayes MD, Morganti A et al. Bosentan Prevents Occurrence But Does Not Speed Healing of Digital Ulcers in Patients with Systemic Sclerosis. ACR meeting 2005, poster L2.
80. Launay D., Diot E.L., Pasquier E.L., Mouthon L., Boullanger N., Fain O., et al. Le bosentan dans le traitement des ulcéres digitaux évolutifs au cours de la sclérodermie systémique (9 cas). Presse Med 35 (2006) 587-592